ARA-290 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
Selectively activates the innate repair receptor (IRR), a CD131/EPOR heterodimer, triggering anti-inflammatory and tissue-protective signaling without any effect on red blood cell production. Suppresses microglia activation and pro-inflammatory cytokine release. Dose-dependently reduces neuropathic pain through central inflammation suppression.
How Does ARA-290 Work in the Body?
ARA-290 (Erythropoietin-derived tissue-protective peptide) is a Innate repair receptor agonist, anti-inflammatory peptide. Synthetic 11-amino acid peptide engineered from the tissue-protective domain of erythropoietin (EPO).
Understanding its mechanism of action helps researchers design protocols and predict outcomes.
What Is the Primary Mechanism of ARA-290?
Selectively activates the innate repair receptor (IRR), a CD131/EPOR heterodimer, triggering anti-inflammatory and tissue-protective signaling without any effect on red blood cell production. Suppresses microglia activation and pro-inflammatory cytokine release. Dose-dependently reduces neuropathic pain through central inflammation suppression.
This mechanism operates at the cellular level and influences downstream pathways that produce the observable effects researchers study.
What Biological Pathways Does ARA-290 Affect?
As a Innate repair receptor agonist, anti-inflammatory peptide, ARA-290 interacts with specific receptors and signaling cascades. These pathways are responsible for the compound's effects on neuropathic pain relief, inflammation reduction, nerve fiber regeneration, improved autonomic function, metabolic control in diabetes.
The multi-pathway activity is what gives ARA-290 its broad potential application range — each pathway contributes to different aspects of the overall effect profile.
How Quickly Does ARA-290's Mechanism Take Effect?
With a half-life of approximately 24 hours, ARA-290 begins interacting with its target receptors within minutes of administration. However, the downstream biological effects take longer to manifest — typically days to weeks depending on the application.
Standard cycles run 28 days typical; 8-16 weeks for extended response because that's the timeframe needed for the mechanism to produce measurable, cumulative results.
What Does the Research Say?
Clinical trials in sarcoidosis-associated small fiber neuropathy and type 2 diabetes showed significant pain reduction and nerve regeneration. A 28-day protocol initiated measurable corneal nerve fiber regrowth. Chronic stress studies showed antidepressant effects comparable to fluoxetine. 4+ completed clinical trials in humans.
The only EPO-derived peptide that completely decouples tissue protection from red blood cell production — providing nerve regeneration without any hematologic effects.
Bottom Line on ARA-290's Mechanism
ARA-290 works through innate repair receptor agonist, anti-inflammatory peptide activity to influence neuropathic pain relief, inflammation reduction, nerve fiber regeneration, improved autonomic function, metabolic control in diabetes. Its mechanism involves multiple pathways, which is why it shows potential across several research applications.
See our ARA-290 benefits guide for how this mechanism translates to practical outcomes.
Complete Guide
ARA-290 : Benefits, Dosage, Side Effects & Research
Related Reading
- ARA-290 Dosage Guide
- ARA-290 Benefits
- ARA-290 Side Effects
- ARA-290 Stacking Guide
- ARA-290 Cycle Guide
- ARA-290 Research
Calculate Your ARA-290 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for ARA-290.
Open Calculator →Research-Grade Sourcing
If you're going to research ARA-290, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is ARA-290?
ARA-290 (Erythropoietin-derived tissue-protective peptide) is a Innate repair receptor agonist, anti-inflammatory peptide. Synthetic 11-amino acid peptide engineered from the tissue-protective domain of erythropoietin (EPO). It is researched for neuropathic pain relief, inflammation reduction, nerve fiber regeneration, improved autonomic function, metabolic control in diabetes.
What is the recommended ARA-290 dosage?
Common dosages: 2-4 mg daily administered once daily via subcutaneous injection. Cycle length: 28 days typical; 8-16 weeks for extended response. Half-life: approximately 24 hours. Use our peptide calculator for exact reconstitution math.
What are the side effects of ARA-290?
Safe profile in multiple clinical trials. Minimal reported adverse events. Occasional mild injection site reactions. No serious safety concerns identified across diabetes, sarcoidosis, and neuropathy patient populations.
Is ARA-290 safe?
ARA-290 has shown a preliminary safety profile in research. Investigational. Underwent Phase II clinical trials. Not FDA-approved. All research should follow appropriate safety protocols.